KDR and hepatocellular carcinoma: Researchers found that ramucirumab and GSK1838705A (VEGFR2 and IGF1R inhibitors) increased the sensitivity of HCC cells to the combination of sorafenib and regorafenib at low concentrations (D''Alessandro et al., 2019).